UBS analyst David Dai lowered the firm’s price target on Kura Oncology (KURA) to $15 from $16 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology price target raised to $30 from $29 at BofA
- Kura Oncology price target lowered to $36 from $38 at Wedbush
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology Earnings Call Highlights Comzifty Launch
- Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook